Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 9, 2021

View Archived Issues

Researchers develop useful murine model of Bardet-Biedl syndrome

MDM2 and MDMX have a p53-independent role in cell-cycle progression in the absence of wild-type p53

Unveiling the evolutionary acquisition of antifungal drug resistance in Candida glabrata

QIMR describes CAR-T cells derived from CD49f+ T cells

Aptamer Sciences patents insulin receptor-specific aptamers

New HSD17B13 inhibitors identified at Inipharm

Glucagon receptor agonists discovered at Intarcia Therapeutics

Prelude Therapeutics presents new Mcl-1 inhibitors

Virulent factors of P. aeruginosa isolates are upregulated under anaerobic conditions

PKM2 is a novel regulator of brown fat adipogenesis

L-WNK1 inhibition as novel therapeutic strategy for protection from glomerular injury

ADX-097 displays targeted complement inhibition in tissues

Brain infections rare but brain symptoms common with SARS-CoV-2

CG-223 demonstrates antifibrotic effects in a murine model of pulmonary fibrosis

Cocrystal Pharma reports pan-viral activity of SARS-CoV-2 main protease inhibitors

MC4 receptor induces antipsychotic drug-related metabolic syndrome

PDS Biotechnology licenses rights to proprietary TARP antigen from NCI

Cybin reports positive preclinical data on deuterated psilocybin analogue

Verve announces preclinical data on GalNAc-LNP technology to deliver ANGPTL3 base editor in NHPs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...